Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

BACKGROUND: Angiogenesis is crucial for glioblastoma growth, and anti-vascular endothelial growth factor agents are widely used in recurrent glioblastoma patients. The number of circulating endothelial cells (CECs) is a surrogate marker for endothelial damage. We assessed their kinetics and explored...

Descripción completa

Detalles Bibliográficos
Autores principales: Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, H M, Walenkamp, A M, Beerepoot, L, Hanse, M, van Linde, M E, Otten, A, Vernhout, R M, de Vos, F Y F, Gratama, J W, Sleijfer, S, van den Bent, M J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506382/
https://www.ncbi.nlm.nih.gov/pubmed/26042933
http://dx.doi.org/10.1038/bjc.2015.191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506382/
https://www.ncbi.nlm.nih.gov/pubmed/26042933
http://dx.doi.org/10.1038/bjc.2015.191

Ejemplares similares